Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial
Neratinib had meaningful activity in selected patients with EGFR exon 18-mutant NSCLC, including patients pretreated with ≥1 TKI. Diarrhea was generally low grade. Given the lack of effective treatments after EGFR TKI failure for NSCLC with uncommon mutations, further examination of neratinib is warranted.
Authors
- Amit Mahipal (ORCID: https://orcid.org/0000-0002-1111-8333)
- Devalingam Mahalingam (ORCID: https://orcid.org/0000-0002-2979-9894)
- Jennifer Marie Suga (ORCID: https://orcid.org/0009-0005-9560-7511)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Christophe Dooms (ORCID: https://orcid.org/0000-0001-7324-7977)
- Jonathan Wade Goldman (ORCID: https://orcid.org/0000-0002-4925-8243)
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- John Paul Crown (ORCID: https://orcid.org/0000-0002-3125-7613)
- M. Antoñanzas (ORCID: https://orcid.org/0000-0002-7434-9059)
- Charles Naltet
- Nisha G Unni (ORCID: https://orcid.org/0000-0003-1549-4720)
- Aviad Zick (ORCID: https://orcid.org/0000-0002-5077-9249)
- A. Martinez Bueno (ORCID: https://orcid.org/0000-0002-5084-2746)
- Judith D. Bebchuk
- Maria J. de Miguel (ORCID: https://orcid.org/0000-0002-9366-8602)
- Barbara Lowenthal
- Lisa D. Eli (ORCID: https://orcid.org/0000-0003-3896-0966)
Institutions
- Northwestern University (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- Institut Gustave Roussy (FR)
- Hospital Clínico San Carlos (ES)
- Hospital Universitario Dexeus (ES)
- St. Vincent's University Hospital (IE)
- Kaiser Permanente Vallejo Medical Center (US)
- Mayo Clinic in Arizona (US)
- Hospital Universitario HM Sanchinarro (ES)
- Northwestern Medicine (US)
- Puma Biotechnology (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical Lung Cancer
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1016/j.cllc.2024.12.003
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- BioMarin Pharmaceutical
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Exelixis
- Jazz Pharmaceuticals
- Clovis Oncology
- Five Prime Therapeutics
- Jounce Therapeutics
- Incyte
- Aminex Therapeutics
- F-star Therapeutics
- NGM Biopharmaceuticals
- Actuate Therapeutics
- Puma Biotechnology
- Silverback Therapeutics
- MacroGenics
- Seagen
- Eisai
- National Institutes of Health
- Genentech
- Chugai Pharmaceutical
- Loxo Oncology
- Principia Biopharma
- National Cancer Institute
- Daiichi Sankyo Europe